神奇製藥(600613.SH):子公司完成7個藥品生產地址更新備案
格隆匯2月11日丨神奇製藥(600613.SH)公佈,公司近日從國家藥監局網站陸續查詢獲知,全資子公司貴州神奇藥業有限公司(簡稱“神奇藥業”)完成了7個藥品(小兒咽扁顆粒、大山楂顆粒、止咳枇杷顆粒、小兒清毒糖漿、板藍根顆粒、通脈顆粒、複方半夏止咳糖漿(半夏露糖漿))的境內生產藥品備案,更新藥品註冊批准文件載明的生產企業地址,並於國家藥監局網站公示備案。
神奇藥業沙文生產研發基地(簡稱“沙文基地”)已通過藥品GMP符合性檢查,該次神奇藥業以上藥品生產地址增加至沙文基地,有助於進一步提升相關藥品質量及滿足市場供應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.